HH Global Holdings operates a scientific practice grounded in peer-reviewed research, accredited laboratory architecture, and a discipline of intellectual independence. Our work supports investors, founders, regulated laboratories, and operators in sectors where the integrity of a scientific finding directly determines commercial, clinical, or regulatory outcome.
Compliance by Design · Method-Validated · Independent · Audit-Ready
Where the off-the-shelf assay does not exist.
A diagnostic, a method, a study, or a platform is only as valuable as the methodology behind it. Our practice is structured to deliver findings that are reproducible by an independent laboratory, defensible to a regulator, and intelligible to a non-specialist board or investment committee. Where claims are made, they are sourced. Where uncertainty exists, it is quantified, not hidden.
Our practice is shaped by four buyer cohorts, each engaging us at a different inflection point in their programme, raise, build, or oversight cycle.
Scientific platform under build. Fractional CSO mandate or investor-grade scientific narrative required for raise, partnership, or board reporting.
Method validation, technical-file authoring, regulator-facing submissions, or scientific oversight on a sponsor–CRO partnership.
Greenfield ISO 17025 / 15189 build, accreditation programme, or upgrade of an existing laboratory to an audit-ready operating model.
Scientific due diligence on a target, second opinion on a portfolio company, or fractional CSO oversight across a hold period.
Each area sits independently. Many engagements draw on two or three together, particularly where a new platform requires lab build, method validation, regulatory positioning, and an investor-grade scientific narrative in the same window. Regulatory and ISO delivery is executed through our subsidiary HH Insight Ltd.
Design, equip, validate, and accredit regulated laboratories. ISO 17025 and ISO 15189 architecture built in from inception, not retrofitted. Delivered through our LabArchitect™ eight-module system.
Molecular and genomic diagnostic development, panel design, and platform validation in non-clinical and clinical settings. Long-read Nanopore, qPCR, and targeted-sequencing workflows complemented by systematic review and meta-analysis at the top of the evidence pyramid.
Method validation, ISO framework implementation, technical files, and regulator-facing documentation for sponsors, CROs, and platform companies. We translate scientific findings into the evidentiary form regulators and standards bodies require.
Fractional Chief Scientific Officer engagements, scientific due diligence for VC and PE, IP strategy and freedom-to-operate review, and board-level scientific narrative for founders raising or scaling regulated platforms.
Systematic reviews, rapid evidence assessments, and methodological appraisal commissioned by government departments, advisory committees, and public-sector procurement teams who require a defensible, peer-reviewable evidence base behind a policy or commissioning decision.
Wilson PB, White SJ et al. "Genomic characterisation of bioaerosols within livestock facilities." Science of The Total Environment, Vol. 918, March 2024.
DOI: 10.1016/j.scitotenv.2024.170722 · FEI-funded study · Long-read Nanopore sequencing identified as the unmet methodological standard across 29 eligible studies for bioaerosol characterisation.
Our practice is sector-independent in method, sector-specific in delivery. We engage where the integrity of a scientific finding directly determines a commercial, clinical, or regulatory outcome.
Panel design, assay validation, and lab-of-record architecture for oncology diagnostic platforms and biomarker programmes.
Method validation, GLP advisory, technical-file authoring, and scientific oversight for sponsor–CRO partnerships in preclinical and translational research.
Companion animal molecular diagnostics, equine genetics, livestock pathogen panels, and bioaerosol characterisation programmes to ISO 17025 standards.
Sampling-to-result method development for food safety, beverage quality assurance, and water-quality microbiome characterisation.
Diagnostic development for wound healing, stoma management, and women's health applications where digital and molecular evidence converge.
Evidence synthesis, systematic review, and methodological appraisal supporting policy, procurement, and advisory-committee decisions.
Buyers of regulated science typically face a binary: an industrial CRO with scale but limited customisation, or a solo academic with depth but no operating infrastructure. Our practice is built to occupy the gap between them.
Scale & capacity
Specialist depth with infrastructure
Depth without delivery
Our scientific practice is led by Dr Samuel White, whose published research, academic post, and platform-building experience anchor the methodological discipline behind every engagement.
Applied immunologist & geneticist · PhD Applied Immunology · Honorary Associate Professor of Translational Immunology, University of Nottingham · 15+ years in translational research, diagnostics & One Health innovation
Applied immunologist and geneticist. Former Associate Professor at York St John University and Director for the Centre of Innovation. Former Senior Lecturer at Nottingham Trent University. Honorary Associate Professor of Translational Immunology at the University of Nottingham. PhD in Applied Immunology. Over 15 years of experience in translational research, diagnostics development, and One Health innovation.
Dr White oversees scientific, regulatory, and operational strategy across the Group. He has led major programmes in translational research, diagnostics development, and One Health innovation, working with partners including the FEI, Chester Zoo, and Universität Bern.
He has held senior academic roles, contributed to high-impact research outputs, advised government and international bodies, and co-founded several biotechnology and health innovation companies.
Patent holder for multiplex lateral flow technology capable of detecting 20–60 analytes simultaneously, and for a plaster-format microneedle diagnostic device. Recognised globally for contributions to bone health research.
Science communicator for The Times, The Telegraph, BBC, and BBC Radio 4. Contributing author profile on The Conversation. Frequent commentator on diagnostic innovation, One Health, and the translation of research into deployable technology.
Peer-reviewed publications across translational immunology, diagnostic method development, and bioaerosol genomics, including the FEI-funded Science of The Total Environment paper cited above. Full bibliography available via ORCID; selected articles featured on the HH Global Holdings Publications page.
Sam is engaged through HH Global Holdings on advisory, fractional, and project mandates within the five areas of practice above. Engagements are scoped, contracted, and delivered through HH Global Holdings as the single accountable party.
These principles are how we keep the practice durable across regulatory regimes, sectors, and commercial pressures.
Our scientific conclusions are independent of the commercial interest of any single counterparty. Where conflicts exist, they are declared.
Every finding is built on a method that is documented, traceable, and reproducible by an independent laboratory.
The science behind our practice is published in the peer-reviewed literature where the field permits, and externally reviewed where it does not.
Methods, records, and reports are written in the form UKAS, MHRA, EMA, FDA and standards bodies expect, from inception, not retrofitted.
Whether you are building a regulated laboratory, validating a diagnostic, raising on a science-led thesis, commissioning an evidence review, or scoping a CRO partnership, we are happy to take an exploratory call.
Open the Contact Form